Lumida
/OPK
⌘K
OPKO Health Inc

OPKO Health Inc

OPK
$1.57USD↑+5.37%+0.08 today

MARKET CAP

1.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $2

52W RANGE

$1
$2

AI Summary

Stalk
Buy NowMedium

OPK is in a Stage 2 advancing uptrend with a primary Bearish Exhaustion pattern signaling seller fatigue and a likely bottoming bounce. Price is currently pulling back into rising 9- and 20-day EMAs on neutral RSI and moderate volume, offering a high-selectivity speculative entry. With no mean-reversion override, the medium-term bias remains bullish, and buying now into this pullback aligns with the speculative strategy’s emphasis on clear structural support.

  • ↑Ended Q2 with $300M+ cash cushioning operations and R&D
  • ↑Raised full-year revenue outlook to $560–585M, up from prior
  • ↓Diagnostics revenue fell to $74.5M in Q2 from $101.1M prior year
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

OPKO Health, Inc. (NASDAQ: OPK) operates in the biotechnology sector, focusing on the development of innovative therapeutics and diagnostic services through its BioReference division. Recently, OPKO has strategically shifted from diagnostics to therapeutics, particularly in oncology and metabolic disease treatments, amid growing market opportunities in these areas, including collaborations with major pharmaceutical companies such as Merck and Regeneron. Given its current trajectory, OPKO is poised to play a significant role in addressing unmet clinical needs in these therapeutic domains.

Bull says

  • ↑Ended Q2 with $300M+ cash cushioning operations and R&D
  • ↑Raised full-year revenue outlook to $560–585M, up from prior
  • ↑Pharma revenue jumped to $89M in Q2 vs. $55.7M year-ago
  • ↑Repurchased $110M of $200M buyback plan, boosting returns
  • ↑Expanding 4K Score test rollout post-FDA label update
  • ↑Partnerships with Regeneron and Merck could unlock >$1B milestones

Bear says

  • ↓Diagnostics revenue fell to $74.5M in Q2 from $101.1M prior year
  • ↓Continues posting negative earnings yield and unprofitable operations
  • ↓Profitability hindered by higher employee benefit and professional costs
  • ↓High stock volatility deters risk-averse investors
  • ↓Small scale limits competitive edge versus larger peers
  • ↓Pipeline drugs risk over-promising without market validation

Investment themes with OPK

Health Care Providers↓ -0.37%

UNH · CVS · HCA

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-02-2026neutral

Transcript signals

Bull points

  • we believe that it will have merits for MASH patients combined with obesity and diabetes. So we will have to look at that.
  • Opco Health's financial results for the second quarter of 2025.
  • we remain on track to achieve cash flow breakeven and positive cash from operations in 2025.

Bear points

  • our plan is to really go into patients who have biomarker evidence of MASH and are obese, okay? And really go into that phase one data on that population of patients that will eventually be of interest if we get both safety and some sign of signal of efficacy with biomarkers.
  • We're going to look for, as any phase one, for safety signals and dosing ranges. And we're not really looking for definitive efficacy, but we will look for biomarker trends that will help us.
  • consolidated operating loss improved slightly during 2025 to $60 million, compared to $61.7 million as a result of the improved results at bioreference partially offset by the increased investments in our pharmaceutical research and development programs.
Read full transcript analysis ›